The next-generation PROMUS Stent is a highly deliverable stent made from cobalt chromium, which allows for thinner struts without sacrificing strength or visibility. The SPIRIT clinical trials indicate that the combination of the polymer/stent platform and the controlled release of the everolimus drug results in excellent deliverability, a strong safety profile, low levels of late loss and improved efficacy, making the PROMUS (XIENCE V) Stent a valuable addition to the U.S. drug-eluting stent market.
Boston Scientific's PROMUS Stent and Abbott's XIENCE V Stent are identical products sold by the respective companies under different brand names. The PROMUS (XIENCE V) Stent is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (up to 28 mm long) with reference vessel diameter of 2.5 to 4.0 mm.
As a result of agreements related to its acquisition of Guidant in 2006, Boston Scientific shares the rights to everolimus-eluting stent technologies with Abbott, including the XIENCE V Everolimus-Eluting Coronary Stent System (marketed by Boston Scientific as the PROMUS Stent). The Company will continue to market its internally developed paclitaxel-eluting TAXUS Stent Systems, which have been the worldwide DES market leaders, implanted in more than four million people. Boston Scientific is also developing paclitaxel- eluting, everolimus-eluting and bare-metal versions of its third-generation Element(TM) Stent, which uses a unique platinum-enriched alloy.
The PROMUS Stent is currently for sale in Europe and certain other
|SOURCE Boston Scientific Corporation|
Copyright©2008 PR Newswire.
All rights reserved